#### Discovery of Bioactive Proteins Derived from Scorpion Venom using Two Dimensional Mass Spectrometry

Meng Li,<sup>1</sup> Yuko P. Y. Lam,<sup>1</sup> Cookson K. C. Chiu,<sup>1</sup> Peng Chen,<sup>2</sup> Rémy Gavard,<sup>1</sup> Christopher A. Wootton,<sup>1</sup> Bryan P. Marzullo,<sup>1</sup> Tomos E. Morgan,<sup>1</sup> Qiong Wu,<sup>2</sup> Mark P. Barrow,<sup>1</sup> Hongzheng Fu,<sup>2</sup> Peter B. O'Connor<sup>1</sup>

<sup>1</sup>Department of Chemistry, University of Warwick, Coventry, UK; <sup>2</sup>Peking University, Beijing, China

#### Pharmacological values of Scorpion Venom

- 1400 species worldwide<sup>1</sup>
- Mesobuthus Martensii, commonly known as Manchurian Scorpion
- Used in traditional Chinese medicines for:
  - Cardiovascular problems<sup>2</sup>
  - Drug dependence<sup>3</sup>
  - Chronic pain<sup>4</sup>
  - ➢ Diabetes<sup>5</sup>
  - ➢ Tumours<sup>6</sup>






- Previous research mainly focused on purification of bioactive venom peptides, and sequences are searched against the database.<sup>3-7</sup>
- 1) Sridhara, S.; Chakravarthy, A. K.; Kalarani, V.; Reddy, D. C., Diversity and Ecology of Scorpions: Evolutionary Success Through Venom, Springer Singapore: 2016; pp 57-80
- 2) Wang, R.; Moreau, P.; Deschamps, A.; de Champlain, J.; Sauvé, R.; Foucart, S.; Bai, L.; Lu, X.-R., Toxicon 1994, 32 (2), 191-200.
- 3) Liu, Y.-F.; Ma, R.-L.; Wang, S.-L.; Duan, Z.-Y.; Zhang, J.-H.; Wu, L.-J.; Wu, C.-F., Protein Expression and Purification 2003, 27 (2), 253-258.
- 4) Goudet, C.; Chi, C.-W.; Tytgat, J., Toxicon 2002, 40 (9), 1239-1258.
- 5) Ortiz, E.; Gurrola, G. B.; Schwartz, E. F.; Possani, L. D., Toxicon 2015, 93, 125-135.
- 6) D'Suze, G.; Rosales, A.; Salazar, V.; Sevcik, C., Toxicon 2010, 56 (8), 1497-1505. Xu, X.; Duan, Z.; Di, Z.; He, Y.; Li, J.; Li, Z.; Xie, C.; Zeng, X.; Cao, Z.; Wu, Y.; Liang, S.; Li, W., Journal of Proteomics 2014, 106, 162-180.
- 3Guan, R.-J.; Xiang, Y.; He, X.-L.; Wang, C.-G.; Wang, M.; Zhang, Y.; Sundberg, E. J.; Wang, D.-C., Journal of Molecular Biology 2004, 341 (5), 1189-1204.



## **Proteins from Scorpion Venom**


- Complex mixture of bioactive proteins
- 113 (proteins) **reviewed**, 103 (genome sequence) **unreviewed** entries from UniProt
- Heavily modified (such as amidation of C-terminus, hydroxylation of proline, and bromination of tryptophan)<sup>1</sup> and crosslinked with multiple disulphide bonds
- Only partial genome sequencing is available
- De novo sequencing is essential for many of these proteins.



- 1) Lewis, R. J.; Garcia, M. L., Nat Rev Drug Discov 2003, 2 (10), 790-802.
- 2) Guan, R.-J.; Xiang, Y.; He, X.-L.; Wang, C.-G.; Wang, M.; Zhang, Y.; Sundberg, E. J.; Wang, D.-C., Journal of Molecular Biology 2004, 341 (5), 1189-1204.
- 3) Mandal, K.; Pentelute, B. L.; Tereshko, V.; Kossiakoff, A. A.; Kent, S. B. H., Journal of the American Chemical Society 2009, 131 (4), 1362-1363.
- 4) Li, C., Guan, R.-J., Xiang, Y., Zhang, Y. & Wang, D.-C. (2005). Acta Cryst. D61, 14-21

# **Search for new anticoagulants**


- Thrombotic diseases
  - > Lead to high blood pressure, heart failure and stroke
  - Current anticoagulants have many disadvantages such as increased gastrointestinal bleeds, bleeding under skin, vomiting blood and bleeding in the brain
- Previous researches shown that scorpion venoms posses anticoagulation properties<sup>2,3</sup>
- Inhibition of Factor Xa (active form of Factor X)
  - > Catalyses the conversion of prothrombin to thrombin<sup>4</sup>
  - One molecule of Factor Xa leads to the formation of approx. 1000 molecules of thrombin<sup>5</sup>
  - Thrombin converts the soluble fibrinogen to insoluble fibrin strands



- 1) Nutescu, E. A.; Shapiro, N. L.; Chevalier, A.; Amin, A. N., Cleve Clin J Med 2005, 72 Suppl 1, S2-6.
- 2) Brazón, J., D'Suze, G., D'Errico, M.L., Arocha-Piñango, C.L., Guerrero, B., 2009, Arch. Toxicol. 83, 669–678.
- 3) Song, Y.M., Tang, X.X., Chen, X.G., Gao, B.B., Gao, E., Bai, L., Lv, X.R., 2005, Toxicon 46, 230–235
- 4) Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007;21:1–11.
- 5) Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504–1514.

# **Search for new anticoagulants**


- Thrombotic diseases
  - > Lead to high blood pressure, heart failure and stroke
  - Current anticoagulants have many disadvantages such as increased gastrointestinal bleeds, bleeding under skin, vomiting blood and bleeding in the brain
- Previous researches shown that scorpion venoms posses anticoagulation properties<sup>2,3</sup>
- Inhibition of Factor Xa (active form of Factor X)
  - > Catalyses the conversion of prothrombin to thrombin<sup>4</sup>
  - One molecule of Factor Xa leads to the formation of approx. 1000 molecules of thrombin<sup>5</sup>
  - Thrombin converts the soluble fibrinogen to insoluble fibrin strands





- 1) Nutescu, E. A.; Shapiro, N. L.; Chevalier, A.; Amin, A. N., Cleve Clin J Med 2005, 72 Suppl 1, S2-6.
- 2) Brazón, J., D'Suze, G., D'Errico, M.L., Arocha-Piñango, C.L., Guerrero, B., 2009, Arch. Toxicol. 83, 669–678.
- 3) Song, Y.M., Tang, X.X., Chen, X.G., Gao, B.B., Gao, E., Bai, L., Lv, X.R., 2005, Toxicon 46, 230–235
- 4) Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007;21:1–11.
- 5) Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504–1514.


## **Standard Proteomics Methods**


#### - Better understand the scorpion venom













NanoLC-MS/MS:Total runtime: 90 minutes Column: RP C18 (15 cm)

No. Proteins:

Observed vs Mascot search: 151 vs 42 (71 peptides)







NanoLC-MS/MS: Total runtime: 90 minutes Column: RP C18 (15 cm)

#### No. Proteins:

Observed vs Mascot search: 151 vs 42 (71 peptides)







NanoLC-MS/MS:Total runtime: 90 minutes Column: RP C18 (15 cm)

No. Proteins:

Observed vs Mascot search: 151 vs 42 (71 peptides)






;)

NanoLC-MS/MS: Total runtime:90 minutes Column RP C18 (15 cm)


#### No. of Proteins:

Observed vs Mascot search: 151 vs 42 (71 peptide)




- Provides complementary information to nLC-MS/MS
- New method for proteomics
- Suitable for venom mixtures
- > 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Potential to avoid the need for separation
- All precursors and their fragments ions can be visualised on one spectrum

1) Simon, H. J.; van Agthoven, M. A.; Lam, P. Y.; Floris, F.; Chiron, L.; Delsuc, M. A.; Rolando, C.; Barrow, M. P.; O'Connor, P. B. Analyst 2016, 141 (1), 157-165.




- Provides complementary information to nLC-MS/MS
- New method for proteomics
- Suitable for venom mixtures
- > 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Potential to avoid the need for separation
- All precursors and their fragments ions can be visualised on one spectrum

1) Simon, H. J.; van Agthoven, M. A.; Lam, P. Y.; Floris, F.; Chiron, L.; Delsuc, M. A.; Rolando, C.; Barrow, M. P.; O'Connor, P. B. Analyst 2016, 141 (1), 157-165.




- Provides complementary information to nLC-MS/MS
- New method for proteomics
- Suitable for venom mixtures
- > 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Potential to avoid the need for separation
- All precursors and their fragments ions can be visualised on one spectrum




1) Simon, H. J.; van Agthoven, M. A.; Lam, P. Y.; Floris, F.; Chiron, L.; Delsuc, M. A.; Rolando, C.; Barrow, M. P.; O'Connor, P. B. Analyst 2016, 141 (1), 157-165.

- Provides complementary information to nLC-MS/MS
- New method for proteomics
- Suitable for venom mixtures
- > 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Potential to avoid the need for separation
- All precursors and their fragments ions can be visualised on one spectrum




#### 2DMS spectrum rotate around x-z axis




1) Simon, H. J.; van Agthoven, M. A.; Lam, P. Y.; Floris, F.; Chiron, L.; Delsuc, M. A.; Rolando, C.; Barrow, M. P.; O'Connor, P. B. Analyst 2016, 141 (1), 157-165.

- Provides complementary information to nLC-MS/MS
- New method for proteomics
- Suitable for venom mixtures
- > 2D contour plot from 3D plot
- Data-independent
- > Suitable for complex samples
- Simple experimental set-up
- Potential to avoid the need for separation
- All precursors and their fragments ions can be visualised on one spectrum




1) Simon, H. J.; van Agthoven, M. A.; Lam, P. Y.; Floris, F.; Chiron, L.; Delsuc, M. A.; Rolando, C.; Barrow, M. P.; O'Connor, P. B. Analyst 2016, 141 (1), 157-165.


- New method for proteomics
- Suitable for venom mixtures
- Provides complimentary information to nLC -MS/MS
- 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Without the need for separation
- All precursors and their corresponding fragments ions can be visualised on one spectrum




- New method for proteomics
- Suitable for venom mixtures
- Provides complimentary information to nLC -MS/MS
- 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Without the need for separation
- All precursors and their corresponding fragments ions can be visualised on one spectrum




- New method for proteomics
- Suitable for venom mixtures
- Provides complimentary information to nLC -MS/MS
- 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Without the need for separation
- All precursors and their corresponding fragments ions can be visualised on one spectrum




- New method for proteomics
- Suitable for venom mixtures
- Provides complimentary information to nLC -MS/MS
- 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Without the need for separation
- All precursors and their corresponding fragments ions can be visualised on one spectrum




- New method for proteomics
- Suitable for venom mixtures
- Provides complimentary information to nLC -MS/MS
- 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Without the need for separation
- All precursors and their corresponding fragments ions can be visualised on one spectrum




- New method for proteomics
- Suitable for venom mixtures
- Provides complimentary information to nLC -MS/MS
- 2D contour plot from 3D plot
- Data-independent
- Suitable for complex samples
- Simple experimental set-up
- Without the need for separation
- All precursors and their corresponding fragments ions can be visualised on one spectrum






- Direct infusion
- All fragments are shown in 1 spectrum
- ➢ 1M x 8192
- Acquisition time: 3 hours
- File size: 93 GB
- Processing time: 4 hours on cluster computers




- Direct infusion
- All fragments are shown in 1 spectrum
- ➢ 1M x 8192
- Acquisition time: 3 hours
- File size: 93 GB
- Processing time: 4 hours on cluster computers


**RP SPE** 




**RP SPE** 




**RP SPE** 




**RP SPE** 




**RP SPE** 





**RP SPE** 



**RP SPE** 









#### **Bottom-up Limitations**

Difficult to tell which peptide come from which undigested proteins  $C_{(cam)} \land T D \land D C_{(cam)} \land R \land K C_{(cam)} P G N P C_{(cam)} R$ 




G9BNP2: T R F AIR CATDADCSR KCPGNPPCR NG F CACT Q9BJX2 : T P F EVR CATDADCSR KCPGNPPCR NG F CACT Q95NK7: T P F AIK CATDADCSR KCPGNPPCR NG F CACT

#### 2DMS of Crude Venom Proteins (Top-down)




Advantages:


- Direct infusion
- Mass range isolation is only needed to obtain better dynamic range
- Acquire all fragments in 1 spectrum
- Acquisition: 3 hours
- > 0.25 mg/mL sample
- ➢ 1M x 8192




- Direct infusion
- Mass range isolation is only needed to obtain better fragmentation
- Acquire all fragments in 1 spectrum
- Acquisition: 3 hours
- > 0.25 mg/mL sample
- ➢ 1M x 8192



Fragment *m/z* 





840

843.0


843.8

844.6

843.8

843.0


844.6








Venom (freeze-dried)















Activity Assay











<u>ت</u> ٥

-1

-2





#### Methodology of obtaining active species **%**60 vcetonitrile ( Venom (freeze-dried) Separation by Venom Milking **C18 SPE Electrical Stimulation** step elution (8-12 V, 128 Hz) <sup>10</sup> Fraction<sup>20</sup> 5 25 30 PLS: Activity PCA: To find correlation between Assav To remove outliers activity and fractions 0.681 2 SD = 2.33423 □ Fractions 250 Crude Venor 200 320.0 F29 160.0 ی ت<sup>2</sup> 150 80.0 F11 40.0 Ξ 0 100 20.0

F20

F23

F30

50

F16

F19

-1

-2


-2 SD = -2.33423


Fractions


10.0

5.0


2.5










- 2DMS of HPLC fraction
- 1M x 4096
- Acquisition time:1.5 hours
- Processing time:2.5 hours





- 2DMS of HPLC fraction
- 1M x 4096
- Acquisition time:1.5 hours
- Processing time:2.5 hours

















Target species(\*)




- Target species(\*)
- 971*m*/*z* and 955 *m*/*z*




- Target species(\*)
- 971*m*/z and 955 *m*/z




- Target species()
- 971 *m/z* and 955 *m/z*
- 971 *m/z* vs 897 *m/z* 
  - ∆mass: 291.060840
  - NeuAc




- Target species()
- 971 *m/z* and 955 *m/z*
- 971 *m/z* vs 897 *m/z* 
  - ∆mass: 291.060840
  - NeuAc
- 955 *m/z* has very similar fragmentation pattern to 897 *m/z*




- Target species()
- 971 *m/z* and 955 *m/z*
- 971 *m/z* vs 897 *m/z* 
  - ∆mass: 291.060840
  - NeuAc
- 955 *m*/*z* has very similar fragmentation pattern to 897 *m*/*z*
  - Maybe related species
- 955 *m/z* vs 897 *m/z* 
  - ∆mass: 288.936236
  - No potential modification mass
  - Future works







- 2DMS of HPLC fraction
- 1M x 4096
- Acquisition time: 1.5 hours
- Processing time:2.5 hours




Autocorrelation Line




- Autocorrelation Line
- Charge reduced species




- Autocorrelation Line
- Charge reduced species




- Autocorrelation Line
- Charge reduced species




- Autocorrelation Line
- Charge reduced species



- Autocorrelation Line
- Charge reduced species



- Autocorrelation Line
- Charge reduced species
- Fragemntation pattern is very different



Fragmentation pattern suggest that this is a labile modification

# Conclusions

- Standard methods
  - Difficult to find new potential pharmaceutical targets
- 2D-FTICR-MS can provide additional information to nLC which is essential to de novo sequencing of unknown proteins and peptides
- Bioactivity assays coupled with PLS helps to narrow down potential pharmaceutical targets
- Potential, novel FXa inhibitor protein sequenced
- 2D allows for easy identification of labile modifications
- Future works
  - Locate the modification site of the NeuAc
  - $\succ$  Find our the modification of the protein with the m/z of 955

# Acknowledgement

University of Warwick: Prof. Peter O'Connor Dr. Mark Barrow Dr. Christopher Wootton Dr. Huilin Li Dr. Yuko Lam Cookson Chiu and all other group members

Peking University: Prof. Hongzheng Fu Peng Chen Qiong Wu Yan Guo



Funding: BBSRC: P021875/1 EPSRC: J003022/1, N021630/1 NST Major Project (China): 2012zx09103201-022 University of Warwick Research Development fund (RD16003)



